Clinical Focus

  • Sleep Medicine

Academic Appointments

Administrative Appointments

  • Assistant Program Director, Stanford Sleep Medicine Fellowship Program (2012 - Present)

Honors & Awards

  • Elected Member, Alpha Omega Alpha Honor Medical Society (2010)

Professional Education

  • Board Certification, Obesity Medicine, American Board of Obesity Medicine (2014)
  • Board Certification: Sleep Medicine, American Board of Internal Medicine (2011)
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2010)
  • Fellowship:Stanford Hospital and Clinics (2011) CA
  • Residency:Baylor College of Medicine (2010) TX
  • Medical Education:Wright State Medical School (2007) OH
  • Undergraduate Education, Georgetown University, Biology (2000)


Journal Articles

  • The Psychiatric Dimensions of Narcolepsy Psychiatric Times Ruoff, C. M., Black, J. 2014; 31 (1): 17 - 21
  • Orthodontics and sleep-disordered breathing SLEEP AND BREATHING Ruoff, C. M., Guilleminault, C. 2012; 16 (2): 271-273

    View details for DOI 10.1007/s11325-011-0534-9

    View details for Web of Science ID 000301737400002

    View details for PubMedID 21559930

  • Hypocretin receptor antagonists for insomnia: rationale and clinical data Clinical Investigation Chad Ruoff, Christian Guilleminault 2012; 2 (6): 623 - 637
  • Oral Appliances and Sleep-Disordered Breathing CHEST Ruoff, C. M., Guilleminault, C. 2011; 140 (5): 1110-1111

    View details for DOI 10.1378/chest.11-1375

    View details for Web of Science ID 000296928500003

    View details for PubMedID 22045873

  • Hypocretin Antagonists in Insomnia Treatment and Beyond CURRENT PHARMACEUTICAL DESIGN Ruoff, C., Cao, M., Guilleminault, C. 2011; 17 (15): 1476-1482


    Hypocretin neuropeptides have been shown to regulate transitions between wakefulness and sleep through stabilization of sleep promoting GABAergic and wake promoting cholinergic/monoaminergic neural pathways. Hypocretin also influences other physiologic processes such as metabolism, appetite, learning and memory, reward and addiction, and ventilatory drive. The discovery of hypocretin and its effect upon the sleep-wake cycle has led to the development of a new class of pharmacologic agents that antagonize the physiologic effects of hypocretin (i.e. hypocretin antagonists). Further investigation of these agents may lead to novel therapies for insomnia without the side-effect profile of currently available hypnotics (e.g. impaired cognition, confusional arousals, and motor balance difficulties). However, antagonizing a system that regulates the sleep-wake cycle while also influencing non-sleep physiologic processes may create an entirely different but equally concerning side-effect profile such as transient loss of muscle tone (i.e. cataplexy) and a dampened respiratory drive. In this review, we will discuss the discovery of hypocretin and its receptors, hypocretin and the sleep-wake cycle, hypocretin antagonists in the treatment of insomnia, and other implicated functions of the hypocretin system.

    View details for Web of Science ID 000295455800009

    View details for PubMedID 21476951

Stanford Medicine Resources: